<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37178267</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Dyslipidemia is not associated with interferon-regulated chemokines or disease activity in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1993</StartPage><EndPage>1995</EndPage><MedlinePgn>1993-1995</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06631-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Solano</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine, Universidad Aut&#xf3;noma Metropolitana-Xochimilco, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amezcua-Castillo</LastName><ForeName>Emanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Preparatory High School Antonio Caso, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amezcua-Guerra</LastName><ForeName>Luis M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-6258-5732</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Mexico City, Mexico. lmamezcuag@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Care Department, Universidad Aut&#xf3;noma Metropolitana-Xochimilco, Mexico City, Mexico. lmamezcuag@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="Y">Dyslipidemias</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>14</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>15</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37178267</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06631-7</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06631-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>O&#x2019;Hagan R, Berg AR, Hong CG, Parel PM, Mehta NN, Teague HL (2022) Systemic consequences of abnormal cholesterol handling: interdependent pathways of inflammation and dyslipidemia. Front Immunol 13:972140. https://doi.org/10.3389/fimmu.2022.972140</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.972140</ArticleId><ArticleId IdType="pubmed">36091062</ArticleId><ArticleId IdType="pmc">9459038</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Zhang Z, Cui Y, Yao G, Ma X, Zhang H (2023) Dyslipidemia is associated with inflammation and organ involvement in systemic lupus erythematosus. Clin Rheumatol. https://doi.org/10.1007/s10067-023-06539-2</Citation></Reference><Reference><Citation>Quevedo-Abeledo JC, Mart&#xed;n-Gonz&#xe1;lez C, Ferrer-Moure C, de Armas-Rillo L, Hernandez-Hernandez MV, Gonz&#xe1;lez-Gay M&#xc1;, Ferraz-Amaro I (2022) Key molecules of triglycerides pathway metabolism are disturbed in patients with systemic lupus erythematosus. Front Immunol 13:827355. https://doi.org/10.3389/fimmu.2022.827355</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.827355</ArticleId><ArticleId IdType="pubmed">35615358</ArticleId><ArticleId IdType="pmc">9124762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorbaninezhad F, Leone P, Alemohammad H, Najafzadeh B, Nourbakhsh NS, Prete M, Malerba E, Saeedi H, Tabrizi NJ, Racanelli V, Baradaran B (2022) Tumor necrosis factor-&#x3b1; in systemic lupus erythematosus: Structure, function and therapeutic implications (Review). Int J Mol Med 49:43. https://doi.org/10.3892/ijmm.2022.5098</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2022.5098</ArticleId><ArticleId IdType="pubmed">35137914</ArticleId></ArticleIdList></Reference><Reference><Citation>Caielli S, Wan Z, Pascual V (2023) Systemic lupus erythematosus pathogenesis: interferon and beyond. Annu Rev Immunol 41:533&#x2013;560. https://doi.org/10.1146/annurev-immunol-101921-042422</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-101921-042422</ArticleId><ArticleId IdType="pubmed">36854182</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora-Arias T, Amezcua-Guerra LM (2020) Type III interferons (Lambda Interferons) in rheumatic autoimmune diseases. Arch Immunol Ther Exp 68:1. https://doi.org/10.1007/s00005-019-00564-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-019-00564-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa-Bautista F, Coronel D, Ramos-Rosillo V, Amezcua-Guerra LM (2022) Performance analysis of Luminex and ELISA to profile serum IP-10 as a biomarker in systemic lupus erythematosus. Lupus 31:1660&#x2013;1665. https://doi.org/10.1177/09612033221122978</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221122978</ArticleId><ArticleId IdType="pubmed">36040216</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzo L, Lindblom J, Mohan C, Parodis I (2022) Current insights on biomarkers in lupus nephritis: a systematic review of the literature. J Clin Med 11:5759. https://doi.org/10.3390/jcm11195759</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11195759</ArticleId><ArticleId IdType="pubmed">36233628</ArticleId><ArticleId IdType="pmc">9570701</ArticleId></ArticleIdList></Reference><Reference><Citation>Albar Z, Wijaya LK (2006) Is there a relationship between serum C-reactive protein level and dyslipidaemia in systemic lupus erythematosus? Acta Med Indones 38:23&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">16479028</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu XR, Qi YY, Zhao YF, Cui Y, Zhao ZZ (2023) Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients. Ren Fail 45:2174355. https://doi.org/10.1080/0886022X.2023.2174355</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2023.2174355</ArticleId><ArticleId IdType="pubmed">36946374</ArticleId><ArticleId IdType="pmc">10035946</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>